Suggestions
Ben Sklaroff
Co-Founder at Genesis Therapeutics
Ben Sklaroff is a prominent figure in the biotechnology sector, serving as the Co-Founder and Vice President of Engineering at Genesis Therapeutics, a company he co-founded in 2019. Genesis Therapeutics focuses on leveraging artificial intelligence to enhance drug discovery processes, particularly targeting difficult-to-treat diseases. The company is known for its proprietary AI platform, GEMS (Genesis Exploration of Molecular Space), which integrates physics-based computational chemistry with machine learning to develop novel drug compounds.15
Education and Early Career
Ben Sklaroff holds a Bachelor of Science degree in Electrical Engineering and Computer Science from the University of California, Berkeley. His early career included roles as a Software Engineering Intern at notable companies such as Facebook, Trifacta, and Boundless Learning. He also served as a Teaching Assistant for an upper-division course at UC Berkeley, indicating his commitment to education and mentoring.7
Professional Experience
Before his current role at Genesis Therapeutics, Sklaroff was the Director of Software Engineering at Markforged. His diverse experience in software engineering has equipped him with skills in various programming languages and technologies, including Python, Java, C++, and machine learning.23
Achievements
Under his leadership, Genesis Therapeutics has secured significant funding, including a recent $200 million Series B round aimed at advancing its AI-driven drug discovery initiatives. The company has also established partnerships with major pharmaceutical firms like Genentech and Eli Lilly.56 In recognition of his contributions to the field, Sklaroff was named in the 2020 Forbes 30 Under 30 list for his work in healthcare innovation.8
Current Role
As VP of Engineering at Genesis Therapeutics, Sklaroff plays a crucial role in guiding the company's technological advancements and strategic direction. His work continues to impact the landscape of biotechnology through innovative approaches to drug development.14